{
    "clinical_study": {
        "@rank": "9847", 
        "arm_group": [
            {
                "arm_group_label": "Magnesium sulfate group", 
                "arm_group_type": "Experimental", 
                "description": "In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h."
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effects of MgSO4 administration on the\n      pharmacodynamics of rocuronium in patients with 60 or more years of age."
        }, 
        "brief_title": "Magnesium Sulphate and Rocuronium in Patients Over 60", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": "Head and Neck Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  60 years or older\n\n          -  ASA physical status I-III\n\n          -  Scheduled for elective oncologic head and neck surgery\n\n        Exclusion Criteria:\n\n          -  Severe renal insufficiency (calculated creatinine clearance < 30 ml/min)\n\n          -  Pre-operatory serum magnesium values > 2.5 mEq/l\n\n          -  Patients receiving medications known to affect neuromuscular function (furosemide,\n             aminoglycoside, anticonvulsivants, calcio channel blocker, litium, azatioprine,\n             cyclofosfamide)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804205", 
            "org_study_id": "MgRoc 60"
        }, 
        "intervention": {
            "arm_group_label": "Magnesium sulfate group", 
            "description": "MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h", 
            "intervention_name": "Magnesium Sulfate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Magnesium Sulfate", 
                "Rocuronium"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "magnesium sulfate", 
            "rocuronium", 
            "neuromuscular block", 
            "onset time", 
            "elderly"
        ], 
        "lastchanged_date": "March 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rio de Janeiro", 
                    "country": "Brazil", 
                    "zip": "20230130"
                }, 
                "name": "Instituto Nacional de C\u00e2ncer"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Magnesium Sulphate on the Pharmacodynamics of Rocuronium in Patients 60 Years or Older: Randomised and Double-Blind Study", 
        "overall_official": {
            "affiliation": "Instituto Nacional de Cancer", 
            "last_name": "Pedro Rotava, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Time from the start of injection of rocuronium until TOF ratio 0.9", 
            "measure": "Total recovery time of neuromuscular block (DurTOF0.9)", 
            "safety_issue": "No", 
            "time_frame": "Within the surgical procedure"
        }, 
        "reference": [
            {
                "PMID": "9301400", 
                "citation": "Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth. 1997 Jul;79(1):122-4."
            }, 
            {
                "PMID": "19919585", 
                "citation": "Czarnetzki C, Lysakowski C, Elia N, Tram\u00e8r MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: a randomised study. Acta Anaesthesiol Scand. 2010 Mar 1;54(3):299-306. Epub 2009 Nov 16."
            }, 
            {
                "PMID": "17635389", 
                "citation": "Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007 Aug;51(7):789-808."
            }, 
            {
                "PMID": "22150409", 
                "citation": "Dubois PE, Gourdin M, Jamart J, Broka SM, Eucher P, D'Hollander A. Early and late parameters describing the offset of neuromuscular blockade are highly intercorrelated. Acta Anaesthesiol Scand. 2012 Jan;56(1):76-82. doi: 10.1111/j.1399-6576.2011.02596.x."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804205"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto Nacional de Cancer, Brazil", 
            "investigator_full_name": "Pedro Rotava", 
            "investigator_title": "Mr", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from the start of injection of rocuronium until 95% depression of the first twitch (T1) of the TOF", 
                "measure": "Onset time", 
                "safety_issue": "No", 
                "time_frame": "Within the surgical procedure"
            }, 
            {
                "description": "Time from the start of injection of rocuronium until T1 of the TOF had recovered to 25% of the initial T1 value", 
                "measure": "Clinical duration (Dur25%)", 
                "safety_issue": "No", 
                "time_frame": "Within the surgical procedure"
            }, 
            {
                "description": "Time between 25% and 75% recovery of the initial T1 value", 
                "measure": "Recovery index (Dur25-75%)", 
                "safety_issue": "No", 
                "time_frame": "Within the surgical procedure"
            }, 
            {
                "description": "Time between 25% recovery of the initial T1 value and a TOF ratio of 0.9", 
                "measure": "Recovery time (Dur25%TOF0.9)", 
                "safety_issue": "No", 
                "time_frame": "Within the surgical procedure"
            }
        ], 
        "source": "Instituto Nacional de Cancer, Brazil", 
        "sponsors": {
            "collaborator": {
                "agency": "Instituto Nacional de Cancer, Brazil", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pedro Rotava", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}